

# Clinical Care Session of the 2025 Annual Cure SMA Research and Clinical Care Meeting

## Continuing Medical Education Information

### **General Information**

- Cure SMA Clinical Care Session
- Wednesday June 25<sup>th</sup>, 2025 at the Grand Californian Disneyland Hotel, Anaheim, CA
- Jointly provided by Postgraduate Institute for Medicine and Cure SMA

### **Target Audience**

- This activity is intended for healthcare professionals engaged in the care of patients with Spinal Muscular Atrophy.

### **Educational Objectives**

*After completing this activity, the participant should be better able to:*

Clinical Care Session Goals include:

- Provide a collaborative platform where healthcare providers from any discipline can exchange knowledge and expertise.
- promote partnerships and research collaborations across healthcare organizations to advance clinical care for SMA.
- Promote mentorship and engagement between emerging clinicians and established leaders in SMA clinical care.
- Encourage meaningful dialogue between individuals and families living with SMA, clinicians, researchers, and industry partners.
- Strengthen the delivery of multidisciplinary, comprehensive care for individuals with SMA.

### **Disclosure of Conflicts of Interest**

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

The PIM planners and others have nothing to disclose. The Cure SMA planners have nothing to disclose.

### **Faculty Disclosures**

Sally Dunaway Young, PT, DPT  
Grant/Research Support: Cure SMA

Hank Mayer, MD  
Speakers/Honoraria non CME: Sanofi

Consultant/Advisory Board: Biogen, Scholar Rock, Roche

Consultant/Advisory Board: Catalyst, Novartis, Roche  
Other financial or material support: IDMC for Scholar Rock

Angelena Edwards, MD  
No financial relationships to disclose

Katlyn McGrattan, PhD  
Grant/Research Support: Swallowing Degradation in Untreated Natural History  
Consultant/Advisory Board: Novartis, Genentech, Roche

Danny Florez-Paz, PhD  
No financial relationships to disclose

Brian Snyder, MD, PhD  
Grant/Research Support: NIH R01  
Consultant/Advisory Board: OrthoPediatric. Alcyone

Robert Graham, MD  
Consultant/Advisory Board: Astellas Pharmaceuticals, XLMTM gene therapy trials consultant  
Elizabeth Harding, PT, EdD  
No financial relationships to disclose

Douglas Storm, MD  
No financial relationships to disclose  
  
Eduardo Tizzano, MD, PhD  
Speakers/Honoraria: Biogen, Roche, Novartis  
Consultant/Advisory Board: Biogen, Roche, Novartis, Scholar Rock

Allyson Henkel  
Employer: Phoenix Language Services

Gretchen Weatherly, PhD,LP  
No financial relationships to disclose

Kyle Loh, PhD  
No financial relationships to disclose

Sarah Wright, DO  
Consultant/Advisory Board: Genentech, Sarepta, Biogen

### **Joint Accreditation Statement**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Cure SMA.

Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Credit Designation**

Up to 5.5 hours of CME will be available through the following:

### **Physician Continuing Medical Education**

The Postgraduate Institute for Medicine designates this CME activity for a maximum of 5.5 [OBJ] *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Continuing Nursing Education**

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.5 contact hours.

### **Continuing Pharmacy Education**

Postgraduate Institute for Medicine designates this continuing education activity for 5.5 contact hours [OBJ] (.55 CEUs) of the Accreditation Council for Pharmacy Education.

UAN JA4008162-9999-25-482-L99-P

### **Interprofessional Continuing Education**



This activity was planned by and for the healthcare team, and learners will receive 5.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

### **International Association for Continuing Education and Training (IACET)**

Postgraduate Institute for Medicine is accredited by the International Association for Continuing Education and Training (IACET) and is authorized to issue the IACET CEU.

Postgraduate Institute for Medicine is authorized by IACET to offer .55 CEUs for this program.

### **National Society of Genetic Counselors**

Genetic Counselors may choose to submit an application to NSGC for Category 2 CEUs after attending this event. Applications and all supporting materials must be submitted within 90 days of the event end date and can expect CEU approval within 10 weeks from the date of submission. If you need additional guidance on how to submit Category 2 CEUs, please email [ceu@nsgc.org](mailto:ceu@nsgc.org).